Myocardial Injury After Ibrutinib Initiation for Hematologic Malignancies

Buck, Benjamin; Chum, Aaron; Patel, Mital; Carter, Rebecca R.; Nawaz, Haseeb; Yıldız, Vedat; Ruiz, Patrick; Wiczer, Tracy; Rogers, Kerry A.; Awan, Farrukh T.; Bhat, Seema A.; Guha, Avirup; Kittai, Adam; Simonetti, Orlando P.; Raman, Subha V.; Wallace, Grant; Sánchez, R. Rubio; Bonsu, Janice M.; Gambril, John A.; Haddad, Devin; Mann, James B.; Wei, Lai; Byrd, John C.; Woyach, Jennifer A.

doi:10.1016/s0735-1097(22)02929-1

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, current evidence indicates that the presence of preexisting AF may increase the risk of HF, particularly in patients using ibrutinib. Similarly, a significant proportion of individuals on ibrutinib may show signs of myocardial fibrosis on cardiovascular magnetic resonance (CMR) imaging [ 69 ].…”

Section: Class Effect Profile and Adverse Events Management: Btk Inhi...mentioning

confidence: 99%

“…The use of ibrutinib has been linked to reversible non-ischemic cardiomyopathy. Symptoms such as systolic dysfunction, decline in left ventricular ejection fraction, and reversible heart failure are likely indicators [ 69 ]. Takotsubo cardiomyopathy, also known as apical ballooning syndrome or stress cardiomyopathy [ 77 ], was a reported adverse effect in patients treated with tyrosine kinase inhibitors, and, some years ago, a case report on mid-cavitary Takotsubo cardiomyopathy post-ibrutinib therapy was described [ 78 ].…”

Section: Class Effect Profile and Adverse Events Management: Btk Inhi...mentioning

confidence: 99%

See 1 more Smart Citation

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Galitzia,

Maccaferri,

Mauro

et al. 2024

Cancers

View full text Add to dashboard Cite

The treatment landscape for CLL has undergone a profound transformation with the advent of targeted agents (TAs) like Bruton’s Tyrosine Kinase inhibitors (BTKis) and BCL-2 inhibitors (BCL-2is). These agents target crucial cellular pathways in CLL, offering superior efficacy over traditional chemo-immunotherapy, which has led to improved progression-free and overall survival rates. This advancement promises enhanced disease control and potentially normal life expectancy for many patients. However, the journey is not without challenges, as these TAs are associated with a range of adverse events (AEs) that can impact treatment efficacy and patient quality of life. This review focuses on detailing the various AEs related to TA management in CLL, evaluating their frequency and clinical impact. The aim is to present a comprehensive guide to the effective management of these AEs, ensuring optimal tolerability and efficacy of TAs. By reviewing the existing literature and consolidating findings, we provide insights into AE management, which is crucial for maximizing patient outcomes in CLL therapy.

show abstract

Section: Class Effect Profile and Adverse Events Management: Btk Inhi...mentioning

confidence: 99%

Section: Class Effect Profile and Adverse Events Management: Btk Inhi...mentioning

confidence: 99%

Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents

Galitzia,

Maccaferri,

Mauro

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“… 40 , 41 Although no common features have been observed among the sporadic reports, in the literature, a preclinical study has found parallel myocardial inflammation and fibrosis injury in the animal models. 42 A rare case of takotsubo cardiomyopathy (TC) was recently reported. 43 This study aims to review the incidence and potential underlying mechanisms of ibrutinib-associated cardiotoxicity, as well as the recommended management options from the pertinent clinical-pharmaceutical aspect.…”

Section: Introductionmentioning

confidence: 99%

“…Systolic dysfunction, deterioration of the left ventricular ejection fraction, and reversible heart failure were probable symptoms. 42 , 73 , 74 Takotsubo cardiomyopathy (TC), also called apical ballooning syndrome or stress cardiomyopathy , was a reported adverse effect in patients with cancer treated with TKIs. 75 A case report described mid-cavitary Takotsubo cardiomyopathy post ibrutinib therapy.…”

Section: Introductionmentioning

confidence: 99%

Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical

Dong¹,

Yan²,

Zeng³

et al. 2022

DDDT

View full text Add to dashboard Cite

Ibrutinib is the first-in-class Bruton tyrosine kinase (BTK) inhibitor that has revolutionized the treatment of B cell malignancies. Unfortunately, increased incidences of cardiotoxicity have limited its use. Despite over a decade of research, the biological mechanisms underlying ibrutinib cardiotoxicity remain unclear. In this review, we discuss the pharmacological properties of ibrutinib, the incidence and mechanisms of ibrutinib-induced cardiotoxicity, and practical management to prevent and treat this condition. We also synopsize and discuss the cardiovascular adverse effects related to other more selective BTK inhibitors, which may guide the selection of appropriate BTK inhibitors.

show abstract